Baxter International Inc.'s BioPharma Solutions business has begun an approximately 1,750 square meter capacity expansion at the company's fill/finish cytotoxic contract manufacturing facility in Halle (Westfalen), Germany. The facilit… Read More »
Bristol-Myers Squibb and PDL BioPharma, Inc. entered an agreement for the global development and commercialization of PDL’s anti-CS1 antibody, elotuzumab, currently in Phase I development for multiple myeloma.
Elotuzumab o… Read More »
A recent study by the Tufts Center for the Study of Drug Development found that how drug developers organize their companies affects operational and financial performance. The research, developed by Tufts CSDD and PRTM, an operations management consu… Read More »